QPS unveils new preclinical research facility in Taipei

QPS unveils new preclinical research facility in Taipei

by admin December 15, 2022 December 15, 2022 No comments

QPS, a global contract research organization, recently opened a second preclinical research facility in Taipei, Taiwan.

The new facility will be operational in December 2022 and will give QPS significant additional flexibility in study scheduling and additional space to grow the existing toxicology business and to build the new pharmacology unit.

Designed to ensure that the utmost care is taken with all toxicology and pharmacology studies, this new research facility boasts well equipped, fully accredited animal centers and a state-of-the-art pharmacology unit. Initially, the center will focus on augmenting the current multi-species capabilities in wound healing models, with pharmacology services in irritable bowel disease (IBD), non-alcoholic steatohepatitis (NASH) and atopic dermatitis. The team will be ready to conduct these studies in a variety of species in early 2023.

QPS has hired Dr. Mei-Ling Hou, PhD to lead the new pharmacology department. Hou joins QPS from the Department of Pharmacology and Toxicology at the Institute for Drug Evaluation Platform, Development Center for Biotechnology (DCB).


Leave comments

Your email address will not be published.*

<br><br>You may use these <abbr title="HyperText Markup Language">HTML</abbr> tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Supportscreen tag